Eric Haura is an Oncology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 1,000 publications with 25,397 citations (h-index 79); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Tampa, FL 336129416
Telephone
813-745-3980Registry record last updated 11 Feb 2008.
Clinical trials
- Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Scientific Affairs, LLCProgram year20223 payments
- Genentech, Inc.Program year20221 payment
- Janssen Scientific Affairs, LLCProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
15 NIH research awards on record, funded 2007–2026 per NIH RePORTER. The latest:
- Fragment-based targeting of EMT-mediated resistance in EGFR-mutant lung cancer
H. Lee Moffitt Cancer Ctr & Res Inst
FY2026$433,256R21CA302981 - Identifying Metabolic Vulnerabilities in Lung Cancer
H. Lee Moffitt Cancer Ctr & Res Inst
FY2025$2,032,950P01CA250984 - Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
H. Lee Moffitt Cancer Ctr & Res Inst
FY2025$681,912R01CA262530
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Peter Forsyth, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”